# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ernest Shackleton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX001-SYN-TD
- Date: 1921-09-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cormac Ellingsworth-Daly, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Pre-departure review: exercise test and expedition medical plan. **S**

## History of present illness

Mr. Shackleton returns nine days before his expedition sails, after a symptom-limited exercise test this morning. He has had no chest pain since the stent, has completed 18 sessions of cardiac rehabilitation, and walks briskly every day. The back strain from two weeks ago has settled with heat and acetaminophen, and he has delegated the lifting. He has not smoked for sixteen weeks and takes varenicline. He drinks two drinks at most, on four evenings a week. He takes aspirin, clopidogrel, atorvastatin, ezetimibe, and metoprolol daily. He wants to know what to carry and what to do if his heart gives trouble at sea. **S**

| Element | Detail |
|---|---|
| Angina | None |
| Rehabilitation | 18 sessions completed |
| Back | Strain settled |
| Tobacco | Not smoked for sixteen weeks |
| Alcohol | Two drinks at most on four evenings a week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, fainting, or swelling |
| Respiratory | Negative | No cough or breathlessness |
| Hematologic | Negative | No bleeding beyond occasional bruises |
| Musculoskeletal | Negative | Back pain gone; no muscle aches |

4 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeat every 5 minutes up to 3 doses **S**
- Varenicline 1 mg tablet, one tablet by mouth twice a day after a one-week starter titration **S**
- Metoprolol succinate extended-release 100 mg tablet, one tablet by mouth daily **S**
- Clopidogrel 75 mg tablet, one tablet by mouth daily for six months after the stent (600 mg loading dose before the procedure) **S**
- Ezetimibe 10 mg tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 83 kg; BMI 27.1 kg/m². All vital signs are synthetic.

Total cholesterol: 108 mg/dL; HDL cholesterol: 45 mg/dL; LDL cholesterol: 44 mg/dL; Triglycerides: 95 mg/dL; HbA1c: 5.7% (high); AUDIT-C: 3. All results are synthetic.

## Change since baseline

- Total cholesterol: 246 mg/dL (high) at baseline, 108 mg/dL at this visit **S**
- HDL cholesterol: 38 mg/dL (low) at baseline, 45 mg/dL at this visit **S**
- LDL cholesterol: 168 mg/dL (high) at baseline, 44 mg/dL at this visit **S**
- Triglycerides: 200 mg/dL (high) at baseline, 95 mg/dL at this visit **S**
- HbA1c: 5.9% (high) at baseline, 5.7% (high) at this visit **S**

## Immunizations given today

- Influenza vaccine, 1921-1922 season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 120/76, pulse 58, weight 83.0 kg, BMI 27.1 |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear to auscultation bilaterally |
| Back | Full, painless movement |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic coronary disease after a stent, angina-free** (I25.118). Exercise treadmill test this morning: 11 minutes of the Bruce protocol, about 12.8 METs, stopped for fatigue, with no angina, no ischemic ST changes, no arrhythmia, and a normal blood pressure response. LDL cholesterol 44 mg/dL on atorvastatin and ezetimibe (total 108, HDL 45, triglycerides 95 mg/dL), a 74% reduction and at target. Blood pressure 120/76. Dr. Solberg-Adebayo agrees that he is fit to sail with the plan below; no routine surveillance imaging is needed. **S**
   - Expedition plan: written cardiac summary with ECG, stent card, and medicine list; six months of medicines plus three months' extra, split between two bags; clopidogrel stop date six months after the stent, written on the summary; aspirin for life.
   - An automated external defibrillator, aspirin, nitroglycerin, and emergency cardiac medicines on board; a satellite link to the cardiology team; and an evacuation plan to the nearest cardiac centers at the ports on the route.
   - Cold stress: warm up before heavy work, cover the face in cold wind, layer clothing, and avoid sudden maximal effort in the cold, which raises blood pressure and the heart's demand.
   - Chest pain that lasts more than 5 minutes after one nitroglycerin, or pain at rest: stop, take nitroglycerin, and get the ship's medical team and the satellite link at once.
   - Influenza vaccine given today.
2. **Prediabetes** (R73.03). HbA1c 5.7%, down from 5.9%, with weight down 3 kg. **S**
   - HbA1c on his return.
3. **Nicotine dependence, in early remission** (F17.210). Abstinent for sixteen weeks. **S**
   - Varenicline to 24 weeks; enough on board.
   - No cigarettes in the ship's stores for him; a plan for cravings at sea.
4. **Alcohol use within limits**. AUDIT-C 3, below the threshold for men. **S**
   - Keep to two drinks a day at most at sea.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 120/76 mmHg, at target |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 83.0 kg, BMI 27.1, down 3 kg; active daily |
| Examination | Angina frequency and Canadian Cardiovascular Society class, nitroglycerin use | Every visit | Completed today | No angina since the stent |
| Imaging | Symptom-limited exercise ECG before remote, strenuous travel | Once before departure, as agreed at the consultation | Completed today | 11 minutes (about 12.8 METs); no angina or ischemic changes |
| Imaging | Stress imaging, coronary CT angiography, echocardiography, or invasive angiography | Only for new or worsening symptoms or a change in function despite optimized therapy; no routine surveillance | Not indicated | Asymptomatic; no surveillance imaging |
| Medication safety | Dual antiplatelet therapy: adherence and bleeding | Every visit during dual therapy | Completed today | Both taken daily; no bleeding; stop date for clopidogrel written on the summary |
| Medication safety | Adherence review: aspirin (or dual antiplatelet therapy), high-intensity statin, beta-blocker for angina | Every visit | Completed today | All taken daily; supply for the voyage arranged |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months | Completed today | LDL 44 mg/dL on atorvastatin and ezetimibe; at target; next on his return |
| Laboratory | HbA1c for prediabetes | Every 3 to 6 months while lifestyle change is under way, then yearly | Completed today | 5.7%, from 5.9% |
| Self-management | Tobacco use and cessation support (varenicline with counseling) | Every visit | Completed today | Abstinent for sixteen weeks |
| Survey | Alcohol use (AUDIT-C) and brief intervention | Each visit until within limits | Completed today | AUDIT-C 3 |
| Referral | Cardiac rehabilitation referral | Up to 36 sessions | Completed today | 18 sessions completed; home exercise plan for the voyage |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Periodically | Up to date | PHQ-2 0 at the preventive visit |
| Self-management | Influenza and COVID-19 vaccination review | Yearly | Completed today | Influenza vaccine given today; COVID-19 vaccine declined at the preventive visit |
| Self-management | Remote expedition plan (exercise test, medicines, defibrillator, evacuation, cold stress) | Before departure | Completed today | Summary, medicines, defibrillator, satellite link, evacuation plan, and cold-stress advice in place |

## Goal progress

- No cigarettes from the quit date, confirmed at each visit. Outcome by 1921-09-08: Not smoked since the quit date a week after intake; varenicline continued to 24 weeks. **S**
- LDL cholesterol below 55 mg/dL with at least a 50% reduction by four months. Outcome by 1921-09-08: 44 mg/dL, from 168. **S**
- Blood pressure below 130/80 mmHg by six weeks. Outcome by 1921-06-23: 128/80 at six weeks. **S**
- Free of angina in daily activity, and a symptom-limited exercise test of at least 10 METs without ischemia before departure. Outcome by 1921-09-08: No angina since the stent; about 12.8 METs without angina or ST changes. **S**
- Drinking within the low-risk limit, with an AUDIT-C below 4, by four months. Outcome by 1921-09-08: AUDIT-C 3, from an AUDIT of 12; two drinks at most on four evenings a week. **S**
- At least 15 sessions of cardiac rehabilitation before departure. Outcome by 1921-09-08: 18 sessions completed. **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Virani SS, et al. Circulation 2023;148(9):e9-e119) (2023), American Heart Association and American College of Cardiology
- 2024 ESC Guidelines for the management of chronic coronary syndromes (Vrints C, et al. Eur Heart J 2024;45(36):3415-3537) (2024), European Society of Cardiology
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force
- Prediabetes and Type 2 Diabetes: Screening (2021), U.S. Preventive Services Task Force

## Follow-up

- Review on his return, with lipids and HbA1c. Satellite messages to the clinic and the cardiology team as needed during the expedition. **S**

